Company intelligence / Profile preview
Guangzhou Saliai Stem Cell Science and Technology Co., Ltd.
Guangzhou*, Guangdong*, Chinasaliai.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
Saliai has advanced its human umbilical cord mesenchymal stem cell product into early-stage clinical trials targeting osteoarthritis/knee inflammation. Other programs remain preclinical. The company has been recognized as an innovation leader in China's regenerative medicine sector with over fifty major research projects and more than nine hundred patent applications related to stem cells.
- Therapeutic areas
- Women's HealthRheumatology
- Modalities
- Mesenchymal stem cell therapy (MSC)Human umbilical cord-derived MSCsHuman bone marrow mesenchymal stem cells
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Guangzhou Saliai Stem Cell Science and Technology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangzhou Saliai Stem Cell Science and Technology Co., Ltd..